Difference between revisions of "Periampullary adenocarcinoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !Study !Evidence !Comparator !Efficacy |-" to "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 25%"|Study !style="width: 25%"|Evidence !style="width: 25%"|Comparator !style="width: 25%"|Efficacy |-") |
m (→Placebo) |
||
| Line 44: | Line 44: | ||
|[http://jamanetwork.com/journals/jama/fullarticle/1216477 Neoptolemos et al. 2012 (ESPAC-3)] | |[http://jamanetwork.com/journals/jama/fullarticle/1216477 Neoptolemos et al. 2012 (ESPAC-3)] | ||
|style="background-color:#1a9851"|Phase III (C) | |style="background-color:#1a9851"|Phase III (C) | ||
| − | |5-FU & Leucovorin<br> Gemcitabine | + | |1. 5-FU & Leucovorin<br> 2. Gemcitabine |
|style="background-color:#ffffbf"|Seems not superior | |style="background-color:#ffffbf"|Seems not superior | ||
|- | |- | ||
| Line 52: | Line 52: | ||
===References=== | ===References=== | ||
| − | # Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. [http://jamanetwork.com/journals/jama/fullarticle/1216477 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22782416 PubMed] | + | # '''ESPAC-3:''' Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. [http://jamanetwork.com/journals/jama/fullarticle/1216477 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22782416 PubMed] |
[[Category:Periampullary adenocarcinoma regimens]] | [[Category:Periampullary adenocarcinoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Gastrointestinal cancers]] | [[Category:Gastrointestinal cancers]] | ||
Revision as of 05:13, 29 September 2018
| Section editor | Page editor | ||
|---|---|---|---|
 |
Neeta K. Venepalli, MD, MBA Chicago, IL |
 |
Ivy Abraham, MD Chicago, IL |
0 regimens on this page
0 variants on this page
|
Liver cancer or hepatobiliary cancer comprises cancers that arise within the liver and its hepatocytes (hepatocellular carcinoma) and the biliary tract cancers, which include bile duct cancer/cholangiocarcinoma and gallbladder cancer.
Guidelines
ESMO
- 2016: Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed
NCCN
Adjuvant therapy
Placebo
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Neoptolemos et al. 2012 (ESPAC-3) | Phase III (C) | 1. 5-FU & Leucovorin 2. Gemcitabine |
Seems not superior |
Preceding treatment
- Surgery
References
- ESPAC-3: Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. link to original article PubMed